share_log

Why Is Diabetes Focused Creative Medical Stock Surging On Thursday?

Why Is Diabetes Focused Creative Medical Stock Surging On Thursday?

为什么专注于糖尿病的创意医疗股票在周四飙升?
Benzinga ·  03/08 02:16

Thursday, Creative Medical Technology Holdings Inc (NASDAQ:CELZ) secured FDA authorization for an expanded access therapy using CELZ-201, a cell-based program to manage abnormal glucose tolerance and prevent Type 1 diabetes (T1D) in high-risk individuals.

周四,Creative Medical Technology Holdings Inc(纳斯达克股票代码:CELZ)获得了美国食品药品管理局的授权,允许使用 CELZ-201 进行扩大准入疗法,这是一项基于细胞的计划,用于管理高危人群的异常葡萄糖耐量和预防1型糖尿病(T1D)。

The therapy uses CELZ-201 to potentially prevent T1D onset and is believed to be a first in medical history.

该疗法使用 CELZ-201 有可能预防 T1D 的发作,据信是医学史上的首例。

This personalized medicine approach focuses on a single high-risk patient.

这种个性化医疗方法侧重于单个高风险患者。

CELZ-201 has a multi-target mechanism to address abnormal glucose tolerance, a T1D precursor, at the cellular level. It embodies hope for high-risk individuals, offering a proactive defense against T1D development.

CELZ-201 具有多靶点机制,可以在细胞层面上解决异常的葡萄糖耐量(T1D 前体)。它体现了高风险人群的希望,为T1D的发展提供了积极的防御。

The shares are trading on a higher session volume of 1.262 million compared to the average volume of 67.610K, as per the data from Benzinga Pro.

根据Benzinga Pro的数据,这些股票的交易量更高,为126.2万股,而平均交易量为67.61万股。

Wednesday, the FDA granted Orphan Drug Designation to Creative Medical's CELZ-101, ImmCelz, aimed at preventing allograft rejection in patients undergoing pancreatic islet cell transplantation, a significant advancement for individuals with Type 1 diabetes.

周三,美国食品药品管理局授予Creative Medical的 CELZ-101 immcelZ孤儿药称号,旨在防止接受胰岛细胞移植的患者出现同种异体移植排斥反应,这对于1型糖尿病患者来说是一项重大进步。

CELZ-101 represents an approach in personalized medicine, utilizing the patient's regulatory T cells (Tregs) to combat autoimmune and alloimmune responses that can destroy insulin-producing cells.

CELZ-101 代表了一种个性化医疗方法,利用患者的调节性 T 细胞 (Treg) 来对抗可能破坏产生胰岛素的细胞的自身免疫和同种免疫反应。

Price Action: CELZ shares are up 34.50% at $6.40 on the last check Thursday.

价格走势:在周四的最后一次支票中,CELZ股价上涨34.50%,至6.40美元。

Photo by Towfiqu barbhuiya on Unsplash

照片由 Towfiqu barbuiya 在 Unsplash

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发